Robert L. Clark

Robert L. Clark

Auto-generated profile, based on publicly available information

Robert L. Clark

Artemis Pharmaceutical Research, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 March 2019 in Birth Defects Research
Verified
Journal Article
Open access
PDF file
RCRobert L. Clark
Robert L. Clark
Malaria during pregnancy results in intrauterine growth restriction, fetal anemia, and infant mortality. Women are more susceptible to malaria during pregnancy due to malaria‐induced inflammation and the sequestration of infected red blood cells in the placenta, which bind to the chondroitin sulfate portion of syndecan‐1 on the syncytiotrophoblast and in the intervillous space. Syndecan‐1 is a dimeric proteoglycan with an extracellular ectodomain that is cleaved from the transmembrane domain (referred to as “shedding”) by matrix metalloproteinases (MMPs), likely the secreted MMP‐9. The ectodomain includes four binding sites for chondroitin sulfate, which are proximal to the transmembrane domain, and six distal binding sites primarily for heparan sulfate. This “shedding” of syndecan‐1 is inhibited by the presence of the heparan sulfate chains, which can be removed by heparanase. The intervillous space contains fibrin strands and syndecan‐1 ectodomains free of heparan sulfate. The following is proposed as the sequence of events that leads to and is primarily responsible for sequestration in the intervillous space of the placenta. Inflammation associated with malaria triggers increased heparanase activity that degrades the heparan sulfate on the membrane‐bound syndecan‐1. Inflammation also upregulates MMP‐9 and the removal of heparan sulfate gives MMP‐9 access to cleave syndecan‐1, thereby releasing dimeric syndecan‐1 ectodomains with at least four chondroitin sulfate chains attached. These multivalent ectodomains bind infected RBCs together leading to their aggregation and entrapment in intervillous fibrin. This mechanism suggests possible new targets for anti‐placental malaria drugs such as the inhibition of MMP‐9. Doxycycline is an antimalarial drug which inhibits MMP‐9.

29 May 2014 in IEEE Journal of Selected Topics in Applied Earth Observations and Remote Sensing
Verified
Journal Article
Open access
EPEileen Perry
Eileen Perry
EMElizabeth Mary Morse-McNabb
Elizabeth Mary Morse-McNabb
JNJames Nuttall
James Nuttall
GLGarry J. O Leary
Garry J. O Leary
RCRobert Clark
Robert Clark
This study explored the relationships between moderate resolution imaging spectroradiometer (MODIS) NDVI observations with both measured and simulated fractional green cover (FGrC), leaf area index (LAI), and above ground biomass (AGB) for dryland wheat in Australia. A total of 37 paddocks in north-western Victoria, Australia, were sampled during 2003-2006 for AGB at anthesis, and for FGrC, NDVI (from an active optical sensor), and AGB during 2012. The 2012 FGrC and NDVI measurements were fitted to MODIS NDVI, resulting in positive, linear relationships when the MODIS NDVI values were ≤ 0.80. Measured AGB was also positively, linearly related to MODIS summed NDVI, resulting in an overall R 2 of 0.81 and root mean square error (RMSE) of 1397 kg/ha. Crop simulations were run for the fourteen paddocks from 2003 to 2006, and six paddocks from 2012. Four crop phenological points were selected to extract corresponding NDVI and simulated crop parameters: emergence, peak LAI, the mid-point between emergence and peak LAI, and anthesis. Linear models were fit between the MODIS NDVI and simulated values of FGrC, LAI, and AGB. Overall, the highest R 2 values corresponded to using all of the dates for FGrC (R 2 = 0.82) and AGB (R 2 = 0.92), and anthesis dates for LAI (R 2 = 0.74). For FGrC and AGB, the RMSE with simulated parameters were comparable or better than the equivalent results from the in situ measurements (note that there were no LAI in situ measurements to compare with). The results support the notion for extending the value of the MODIS NDVI using crop simulation models. The combination of remotely sensed and simulation data might offer regional maps of spatial AGB and ultimately grain yield, which would have high value for research, resource management, policy, and potentially, crop management.

17 August 2010 in Birth Defects Research Part B: Developmental and Reproductive Toxicology
Verified
Journal Article
Closed access
PDF file
RCRobert L. Clark
Robert L. Clark
WGWilliam E. Gristwood
William E. Gristwood
RLRichard Lewsley
Richard Lewsley
RWRobert Wilson
Robert Wilson
AHAndrew W. Harrell
Andrew W. Harrell

24 June 2017 in Birth Defects Research
Verified
Journal Article
Open access
PDF file
RCRobert L. Clark
Robert L. Clark
The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester. This may soon change to recommending artemisinin‐based combination therapies (standard duration of dosing = 3 days). The non‐artemisinin partner drugs include amodiaquine, lumefantrine, mefloquine, piperaquine, sulfadoxine+pyrimethamine, and pyronaridine. For quinine, clindamycin, and mefloquine and the combinations of sulfadoxine+pyrimethamine and artemether+lumefantrine, there are reports (including studies without internal comparison groups) that combined describe 304 to >1100 exposures of women in the first trimester for each drug with no conclusive evidence of adverse effects on pregnancy at therapeutic doses. This is despite the fact that all of these drugs or drug combinations caused embryo deaths and/or malformations in at least one animal species and all except lumefantrine had at least one exposure ratio <1.It now seems that these animal studies overestimated the risk of developmental toxicity in women with malaria. Three other non‐artemisinins (amodiaquine, piperaquine, and pyronaridine) have few or no reported exposures in women in the first trimester and have exposure ratios ≤2 based on studies in pregnant rats and rabbits with dosing throughout organogenesis. However, none of these drugs caused embryo deaths or malformations in pregnant rats and rabbits with the exception of pyronaridine, which caused embryo deaths only at a dose that was excessively toxic to the mothers. Thus, for amodiaquine, piperaquine, and pyronaridine, the testing in animals did not reveal findings of concern and the exposure ratios were in the range of the other non‐artemisinin antimalarials described above. Birth Defects Research 109:1075–1126, 2017. © 2017 The Authors. Birth Defects Research Published by Wiley Periodicals, Inc.

20 October 2020 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
RCRobert L. Clark
Robert L. Clark